In 2016, a study carried out on humanized mice evaluated TGN1412’s effects on the immune system, and confirmed that it could cause cytokine release syndrome, destruction of white blood cells, and other negative effects observed during the initial human trial.
What happened to patients in the 2006 drug trial for Monoclonal Antibodies?
The patients had suffered an extreme immune response called a cytokine storm. They were given huge doses of steroids and kept alive by machines as their vital organs shut down. Doctors did not know if they would survive and told relatives to say their goodbyes.
What was TGN1412 supposed to do?
TGN1412 was meant to work by controlling the human body’s white blood cells. Solari said: “In rheumatoid arthritis the body’s immune system attacks itself. TGN1412 was intended to deactivate the immune system. However, most antibody products, including TGN1412, are also tested on monkeys.
What was Theralizumab used for?
Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).
What is a mAb drug?
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer.
Why did TGN1412 fail?
It is likely that activation of CD4+ effector memory T-cells by TGN1412 was responsible for the cytokine storm. Lack of CD28 expression on the CD4+ effector memory T-cells of species used for pre-clinical safety testing of TGN1412 offers an explanation for the failure to predict a ‘cytokine storm’ in humans.
How was TGN1412 administered?
The mAb was administered by IV infusion (duration of 3 to 6 minutes) to six healthy subjects at a starting dose of 0.1 mg/kg. This dose was reported to be 1/500th of the safe animal dose.
Was TGN1412 tested on animals?
According to TeGenero, the drug has been tested extensively in laboratory animals including rabbits, dogs and monkeys with no drug-related adverse events. However, several studies have pointed out crucial species differences between humans and monkeys in the particular function of the immune system.
What are the risks of monoclonal antibodies?
Some possible risks from antibody treatment are: It may interfere with your body’s ability to fight off a future infection of SARS-CoV-2. It may reduce your body’s immune response to a vaccine for SARS-CoV-2.
What is Sentinel dosing?
A strategy called sentinel dosing is often practiced so that one person in the first cohort of participants is dosed in advance of the full study. This ensures that if adverse events manifest quickly, as few participants as possible are impacted.
What is the TGN1412 trial?
TGN1412 was the trial name for a type of monoclonal antibody therapy manufactured by German firm TeGenero.
Why can’t we predict a ‘cytokine storm’ in TGN1412?
Lack of CD28 expression on the CD4+ effector memory T-cells of species used for pre-clinical safety testing of TGN1412 offers an explanation for the failure to predict a ‘cytokine storm’ i … Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells
Is TGN1412 making a comeback as an arthritis treatment?
Two years ago it was revealed TGN1412 was making an astonishing comeback as a potential treatment for arthritis. The rights were bought by Russian company TheraMAB which renamed it TAB08. Trials were once again being conducted on humans – but at just five per cent the dose used in the Elephant Man tests.
Is the TGN1412 material tampered with?
Very quickly, tests showed that the TGN1412 used in the study had not been tampered and was identical to the materials used in the pre-clinical safety tests performed in tissue culture and in animals. So why hadn’t these tests spotted any problems?
